Clinical Trial Details

EORTC-22996-24002

Back to Clinical Trials Database

A phase III double-blind, randomized, placebo-controlled study of Erythropoietin when used as an adjuvant to radiation therapy in patients with head and neck squamous cell carcinoma. EORTC 22996-24002

Study documentation

Trial Status All trial activities ended
Dates Date of activation: 12-Mar-2001
Date Step1 close: 04-Apr-2003
Data management at EORTC Yes
Design Phase 3
Randomized open
Targeted Sample size EORTC Groups: 762
Treatment Recombinant human erythropoietin alfa
Study Staff
Type of cancer
Participating groups EORTC Head and Neck Cancer Group
EORTC Radiation Oncology Group
Arbeitsgemeinschaft Radiologische Onkologie
Groupe d'Oncologie et Radiotherapie Tete et Cou
Trans-Tasman Radiation Oncology Group Inc
Radius Hungaricus Oncology Group
Participating centers
Protocol summary http://clinicaltrials.gov/ct/show/NCT00017277
NCT number NCT00017277